Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Griffin, M. O.
  • Jinno, M.
  • Miles, Lindsey
  • Villarreal, F. J.

publication date

  • February 2005

journal

  • Molecular and Cellular Biochemistry  Journal

abstract

  • Myocardial ischemia-reperfusion (I/R) is associated with the activation of matrix metalloproteinases (MMPs) and serine proteases. We hypothesized that activation of MMPs and the serine protease plasmin contribute to early cardiac myocyte death following I/R and that broad-spectrum protease inhibition with doxycycline (DOX) preserves myocyte viability. Rats treated daily with or without DOX beginning 48 h prior to experimentation were subjected to 30 min of coronary occlusion and 2 days of reperfusion. DOX pre-treatment reduced infarct size by 37%. DOX attenuated increases in MMP-9 and plasmin levels as determined by gelatin zymography and immunoblot, respectively. Neutrophil extravasation was unaltered by DOX as assessed by myeloperoxidase (MPO) activity. To examine the contribution of MMP-9 and plasmin to myocyte injury, cultures of neonatal rat ventricular myocytes (NRVMs) were treated for 48 h with 83 kDa MMP-9 or plasminogen in the presence or absence of DOX. MMP-9 treatment did not affect myocyte viability. Plasminogen treatment led to increased plasmin activity, resulting in loss of beta1-integrin, NRVM detachment and apoptosis. DOX co-treatment inhibited plasmin activity and preserved NRVM attachment, whereas co-treatment with the broad-spectrum MMP inhibitor GM6001 had no effect. These results indicate that plasmin causes disruption of myocyte attachment and viability independently of MMP activation in vitro and that inhibition of plasmin by DOX may reduce I/R-induced myocyte death in vivo through the inhibition of plasmin.

subject areas

  • Animals
  • Animals, Newborn
  • Annexin A5
  • Anti-Bacterial Agents
  • Antigens, CD29
  • Apoptosis
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Doxycycline
  • Fibrinolysin
  • Humans
  • Immunoblotting
  • Inflammation
  • Male
  • Matrix Metalloproteinase 9
  • Microscopy, Phase-Contrast
  • Myocardial Infarction
  • Myocardial Ischemia
  • Myocardial Reperfusion
  • Myocardium
  • Peroxidase
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury
  • Time Factors
  • Up-Regulation
scroll to property group menus

Research

keywords

  • matrix metalloproteinase
  • myocardial ischemia-reperfusion
  • plasmin/plasminogen system
  • proteases
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0300-8177

Digital Object Identifier (DOI)

  • 10.1007/s11010-005-2540-3

PubMed ID

  • 15792348
scroll to property group menus

Additional Document Info

start page

  • 1

end page

  • 11

volume

  • 270

issue

  • 1-2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support